Recursion Income Tax Expense from 2010 to 2024

RXRX Stock  USD 6.95  0.03  0.43%   
Recursion Pharmaceuticals Income Tax Expense yearly trend continues to be fairly stable with very little volatility. Income Tax Expense is likely to outpace its year average in 2024. During the period from 2010 to 2024, Recursion Pharmaceuticals Income Tax Expense regression line of annual values had r-squared of  0.34 and arithmetic mean of (602,993). View All Fundamentals
 
Income Tax Expense  
First Reported
2010-12-31
Previous Quarter
-4.1 M
Current Value
-3.9 M
Quarterly Volatility
2.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Recursion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Recursion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 19.1 M, Interest Income of 19.2 M or Depreciation And Amortization of 25.6 M, as well as many indicators such as Price To Sales Ratio of 43.68, Dividend Yield of 0.0 or PTB Ratio of 4.64. Recursion financial statements analysis is a perfect complement when working with Recursion Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Recursion Pharmaceuticals Correlation against competitors.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Latest Recursion Pharmaceuticals' Income Tax Expense Growth Pattern

Below is the plot of the Income Tax Expense of Recursion Pharmaceuticals over the last few years. It is Recursion Pharmaceuticals' Income Tax Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Recursion Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Income Tax Expense10 Years Trend
Slightly volatile
   Income Tax Expense   
       Timeline  

Recursion Income Tax Expense Regression Statistics

Arithmetic Mean(602,993)
Geometric Mean845,270
Coefficient Of Variation(446.59)
Mean Deviation1,935,589
Median646,000
Standard Deviation2,692,908
Sample Variance7.3T
Range9.3M
R-Value(0.59)
Mean Square Error5.1T
R-Squared0.34
Significance0.02
Slope(352,862)
Total Sum of Squares101.5T

Recursion Income Tax Expense History

2024-3.9 M
2023-4.1 M
2022-55 K
2021-8.4 M
2020876 K

About Recursion Pharmaceuticals Financial Statements

Recursion Pharmaceuticals investors use historical fundamental indicators, such as Recursion Pharmaceuticals' Income Tax Expense, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Recursion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Income Tax Expense-4.1 M-3.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.